New study confirms role of digital biomarkers in monitoring patients with multiple sclerosis
pharmafile | November 11, 2021 | News story | Business Services |
Results from a clinical study, published by Ad Scientiam in ‘Multiple Sclerosis and Related Disorders, secure the place of MSCopilot ® for the self-assessment of the 110,000 patients living with multiple sclerosis (PwMS) in France.
These results show a good correlation of the MSCopilot score with the Expanded Disability Status Scale (EDSS), a reference scale allowing neurologists to assess the status and evolution of MS. The study also shows that the main MSCopilot digital biomarkers (Walking, Vision, Dexterity, and Cognition) enable a more functional analysis of the disease.
In this study, a group of 116 PwMS were studied in 11 expert centers in France. MSCopilot’s capacity to measure handicap was demonstrated through positive correlation with the EDSS. The device allowed researchers to highlight and understand nuances in the different stages of MS that standard tests could not capture.
The digital biomarkers of MSCopilot also made it possible to determine whether the patients’ EDSS score was higher or lower than 3.5. This value represents a threshold towards more debilitating forms of the disease.
Digital biomarkers are patient-generated physiological and behavioural measures, clinically validated and processed by algorithms. These data help to explain, influence, and/or predict health-related outcomes.
MSCopilot captures over 250 digital biomarkers which provide objectivity to MS-related symptoms, and these are recorded through the patients’ smartphones. The results are then shared with their healthcare providers, supplying valuable information for clinical decision-making.
“These data demonstrate that digital biomarkers allow a more accurate assessment of diseases, offering caregivers the opportunity to improve the management of serious and disabling diseases such as multiple sclerosis,” said Dr. Saad Zinaï, Medical Director at Ad Scientiam. “MSCopilot® is set to become a new international standard in clinical trials and real-life patient monitoring.”
Lina Adams
